Phaseline

Companies › Alimera Sciences

Alimera Sciences: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 4, 1 Phase 3; Infectious disease, Ophthalmology; next expected readout Oct 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fluocinolone Acetonide
Glucocorticoid receptor agonist
NR3C1Phase 4Diabetic Macular Edema; Non-infectious Uveitis Affecting the Posterior Segment of the Eye; Diabetic Macular Edema (DME); Radiation RetinopathyOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04469595Fluocinolone AcetonidePhase 4Diabetic Macular EdemaOphthalmologyDec 2024
NCT07843849Fluocinolone AcetonidePhase 4Diabetic Macular Edema (DME)OphthalmologyMar 2028
NCT06539481Fluocinolone AcetonidePhase 4Non-infectious Uveitis Affecting the Posterior Segment of the EyeInfectious diseaseOct 2028
NCT05844982Fluocinolone AcetonidePhase 3Radiation RetinopathyOphthalmologyDec 2029
NCT04910503Fluocinolone AcetonidePhase 4Diabetic Macular EdemaOphthalmologyApr 2030

Targets

NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Laboratorios Sophia S.A de C.V. Optinose US Santhera Pharmaceuticals Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Companies built like this

Laboratorios Sophia S.A de C.V. Santen SAS Oticara Australia Insud Pharma ReGenTree

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.